Intensity-modulated radiotherapy (IMRT)

What it is

Intensity-modulated radiotherapy (IMRT) is an advanced form of external-beam radiation therapy introduced in the 1990s that varies beam intensity to better spare normal tissue. IMRT is a computer-planned version of three-dimensional conformal radiotherapy in which the radiation beam is divided into many small beamlets, and the intensity of each beamlet can be changed. The main practical advantage is that it can shape the high-dose region more closely around a tumour, especially when the target has a complex or concave shape and lies close to sensitive organs such as the spinal cord, salivary glands, bowel, bladder, or rectum.

In plain language, IMRT aims to deliver the prescribed dose to the cancer while reducing unnecessary dose to nearby healthy tissues. This can lower some treatment-related side effects compared with older radiation techniques, although the benefit depends on the cancer site, the anatomy being treated, and the quality of planning and image guidance. In India, IMRT is widely available in many tertiary cancer centres and is commonly used for head and neck, prostate, breast, pelvic, brain, and some gastrointestinal cancers.

A short comparison is useful:

Technique	What changes during treatment planning	Main goal
Conventional RT	Simple beam arrangement	Treat target, less conformal
3D conformal RT	Beam shape matches tumour better	Improve dose shaping
IMRT	Beam shape and beam intensity both vary	Better tumour coverage with more normal-tissue sparing

How it works

IMRT uses detailed imaging, usually CT simulation and sometimes MRI or PET fusion, to map the tumour and nearby organs at risk. A radiation oncologist outlines the target and the normal structures that should receive as little dose as possible. Then a treatment planning system uses inverse planning: the clinician sets dose goals and limits, and the software calculates beam arrangements and beamlet intensities to best meet those goals.

Radiation is usually delivered by a linear accelerator. The machine shapes the beam with a multileaf collimator, a device made of many moving metal leaves. During treatment, these leaves move to create many small beam segments, or the machine may deliver radiation while rotating around the patient in arc-based forms of IMRT such as volumetric modulated arc therapy.

IMRT is often paired with image-guided radiotherapy (IGRT). Imaging done just before or during treatment helps confirm that the patient and tumour are in the planned position. This matters because IMRT uses steep dose gradients, meaning the dose can fall off quickly outside the target. That precision is useful, but it also means setup accuracy is important.

Evidence and uses

IMRT is used across many tumour sites for both curative and palliative treatment. Strongest routine-use evidence is in settings where sparing nearby organs clearly matters, such as head and neck cancer, prostate cancer, breast cancer in selected cases, pelvic cancers, and some central nervous system tumours. Comparative planning studies consistently show that IMRT can produce superior dose distributions compared with older techniques.

Clinical benefit is more nuanced. For some cancers, randomised and non-randomised studies support lower toxicity with IMRT, especially reduced xerostomia in head and neck cancer when salivary glands can be spared, and lower exposure of bowel, bladder, rectum, heart, or lungs in selected situations. For other sites, IMRT improves dosimetry but has not always shown a clear survival advantage over non-modulated radiation. That is not surprising because the main purpose of IMRT is often toxicity reduction and safer dose delivery, not necessarily a direct increase in cure rates.

Common situations where IMRT may be preferred include:

1. Head and neck cancers: to reduce dose to salivary glands, spinal cord, oral cavity, and swallowing structures.
2. Prostate cancer: to limit dose to rectum and bladder.
3. Gynecologic and pelvic cancers: to reduce bowel and bladder exposure.
4. Brain and skull-base tumours: to protect optic structures, brainstem, and normal brain.
5. Breast cancer in selected patients: to improve dose uniformity and reduce dose to heart or lung in some plans.

IMRT can also be used when radiation is combined with chemotherapy, targeted therapy, or immunotherapy, but the combined side-effect profile depends on the full treatment plan. In liver cancer and other abdominal cancers, IMRT may help reduce dose to gastrointestinal organs and uninvolved liver, though careful patient selection remains important.

When to see a clinician

A radiation oncologist should assess whether IMRT is appropriate for a specific cancer. Not every patient needs IMRT, and in some cases another technique such as 3D conformal radiotherapy, stereotactic body radiotherapy, brachytherapy, proton therapy, or surgery may be more suitable. The choice depends on tumour type, stage, location, prior radiation, treatment goal, and access to technology.

Ask your team about:

• why IMRT is being recommended instead of another radiation technique
• the total dose and number of sessions planned
• whether daily image guidance will be used
• expected short-term and long-term side effects for the body area being treated
• whether chemotherapy or other systemic therapy will be given at the same time

During treatment, contact the treating team promptly if you develop severe mouth sores, dehydration, fever, worsening swallowing difficulty, uncontrolled diarrhoea, painful urination, shortness of breath, or skin reactions that are rapidly worsening. These symptoms may need supportive treatment, a treatment break, or reassessment.

Limitations and open questions

IMRT is precise, but it is not automatically better in every case. It requires high-quality imaging, contouring, planning, machine quality assurance, and accurate daily setup. If these steps are weak, the theoretical advantage may not translate into better outcomes. IMRT can also spread a low dose of radiation to a larger volume of normal tissue than some older techniques, which has raised concern about a possible increase in second-cancer risk, especially in younger patients, although the absolute risk for an individual patient is usually small and must be weighed against the expected benefit.

Another limitation is that better dose distribution does not always mean better survival. For many tumour sites, evidence supports lower toxicity more clearly than longer survival. Evidence also varies by disease site, and some uses are supported mainly by planning studies, retrospective series, or mixed-quality comparative data rather than large randomised trials.

Side effects still occur with IMRT because normal tissues near the target often receive some radiation. The pattern depends on the treatment area. Examples include fatigue, skin irritation, hair loss in the treated area, dry mouth, taste change, sore throat, swallowing difficulty, cough, nausea, diarrhoea, bladder irritation, and sexual side effects. Late effects can appear months to years later.

Cost and access are practical issues. IMRT needs specialised equipment, trained staff, and quality systems, so availability may differ between centres. In India, patients may wish to ask whether the centre has routine image guidance, peer review of contours and plans, and experience treating their specific cancer type with IMRT.

Evidence continues to evolve on which patients benefit most, how IMRT should be combined with systemic therapy, and when newer approaches such as adaptive radiotherapy or proton therapy offer meaningful added value over standard IMRT.